Deal or No Deal, AstraZeneca Stock Is a Bargain
The logic of a pharma megamerger is questionable, but AstraZeneca’s record isn’t.
We haven't written up this one. WSJ Markets has the full story — the link below goes straight to it.
More in Finance & Markets
RWAs buck DeFi slowdown as tokenized assets gain traction: CoinShares
Tokenized real-world assets moved beyond issuance as RWA deposits more than tripled to $7.4 billion, while lending and trading activity expanded despite a broader industry slowdown.
Mastercard says UPI complements digital payments ecosystem, not a competitor; sees significant growth potential in India
Mastercard sees India's UPI as a complementary platform for digital payments. This homegrown system has significantly expanded the country's digital payment ecosystem.
IPO market poised for stronger momentum in Q2 FY27 as 146 firms awaits market entry: Axis Capital
The report said 146 companies have already secured approval from the Securities and Exchange Board of India (SEBI) and are awaiting market entry, while another 65 companies have filed their draft red…
Czech Koruna: Softer CNB guidance may weigh against euro – ING
ING strategist Frantisek Taborsky says July Czech inflation at 1.7% year-on-year should have limited impact on the Czech National Bank (CNB) meeting.
Silver price today: Silver broadly unchanged, according to FXStreet data
Silver prices (XAG/USD) broadly unchanged on Thursday, according to FXStreet data. Silver trades at $62.01 per troy ounce, broadly unchanged 0.06% from the $62.05 it cost on Wednesday.
Bursa ends lower on profit taking
Asian equities closed lower as the previous session's tech-led rally lost momentum, with investors locking in gains after the recent rebound in semiconductor and AI-related stocks, says an analyst.